The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! About 1.56 million shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 57.40% since March 8, 2016 and is uptrending. It has outperformed by 48.08% the S&P500.
The move comes after 7 months positive chart setup for the $1.36 billion company. It was reported on Oct, 11 by Barchart.com. We have $38.33 PT which if reached, will make NASDAQ:CLVS worth $272.00 million more.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 EPS, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by WallachBeth Capital given on Thursday, September 10. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Neutral” rating by Goldman Sachs on Tuesday, November 17. The rating was maintained by Mizuho on Wednesday, August 24 with “Neutral”. Suntrust Robinson maintained the shares of CLVS in a report on Friday, September 23 with “Buy” rating. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 21. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned “Buy” rating by Suntrust Robinson on Wednesday, August 24. The firm has “Buy” rating by Suntrust Robinson given on Friday, August 5. The stock has “Buy” rating given by SunTrust on Friday, September 23. The company was maintained on Friday, February 26 by Stifel Nicolaus. Credit Suisse upgraded Clovis Oncology Inc (NASDAQ:CLVS) on Wednesday, September 21 to “Outperform” rating.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.13, from 0.87 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Sabby Mgmt Lc has 0.04% invested in the company for 59,836 shares. Parametric Portfolio Ltd Company holds 0% or 10,461 shares in its portfolio. Balyasny Asset Mgmt Limited Liability has 0.01% invested in the company for 75,000 shares. Blackrock Fund Advisors has 0% invested in the company for 1.27M shares. J Goldman Limited Partnership holds 0.24% or 336,200 shares in its portfolio. Wolverine Asset Mgmt Ltd Limited Liability Company has 10,584 shares for 0% of their US portfolio. Putnam Invs Lc last reported 52,467 shares in the company. Credit Suisse Ag accumulated 122,697 shares or 0% of the stock. Iguana Healthcare Management Lc reported 90,000 shares or 0.5% of all its holdings. Apriem Advisors has 400 shares for 0% of their US portfolio. Secor Cap Advsrs Limited Partnership accumulated 0.02% or 14,081 shares. Consonance Cap Mngmt Limited Partnership accumulated 5.7% or 2.94M shares. Partner Invest Mngmt Lp owns 31,406 shares or 0.71% of their US portfolio. The New York-based Int Grp has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Antipodean Advsr Limited Liability owns 523,000 shares or 4.34% of their US portfolio.
More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Fool.com which released: “Why Clovis Oncology Inc. Rose 52.7% in September” on October 10, 2016, also Fool.com with their article: “Why Clovis Oncology Shares Are Falling 14.5% Today” published on October 07, 2016, Fool.com published: “Is Clovis Oncology Still a Strong Buy?” on September 12, 2016. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Investorplace.com and their article: “Why Clovis Oncology Inc (CLVS), Philip Morris International Inc. (PM) And …” published on September 22, 2016 as well as Streetinsider.com‘s news article titled: “Clovis Oncology (CLVS), Lonza Enter into Manufacturing Services Agreement for …” with publication date: October 04, 2016.
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.